PL4358995T3 - Inhibitor szlaku miostatyny w połączeniu z aktywatorem szlaku glp-1 do stosowania w leczeniu zaburzeń metabolicznych - Google Patents

Inhibitor szlaku miostatyny w połączeniu z aktywatorem szlaku glp-1 do stosowania w leczeniu zaburzeń metabolicznych

Info

Publication number
PL4358995T3
PL4358995T3 PL22744054.2T PL22744054T PL4358995T3 PL 4358995 T3 PL4358995 T3 PL 4358995T3 PL 22744054 T PL22744054 T PL 22744054T PL 4358995 T3 PL4358995 T3 PL 4358995T3
Authority
PL
Poland
Prior art keywords
glp
combination
pathway
metabolic disorders
treating metabolic
Prior art date
Application number
PL22744054.2T
Other languages
English (en)
Polish (pl)
Inventor
Kimberly LONG
Yung CHYUNG
George NOMIKOS
Jeffrey S. Flier
Micah T. WEBSTER
Christopher CHAPRON
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82608742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4358995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of PL4358995T3 publication Critical patent/PL4358995T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL22744054.2T 2021-06-23 2022-06-22 Inhibitor szlaku miostatyny w połączeniu z aktywatorem szlaku glp-1 do stosowania w leczeniu zaburzeń metabolicznych PL4358995T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163214234P 2021-06-23 2021-06-23
US202163260136P 2021-08-10 2021-08-10
US202163260254P 2021-08-13 2021-08-13
US202263266348P 2022-01-03 2022-01-03
US202263269702P 2022-03-21 2022-03-21
PCT/US2022/034588 WO2022271867A1 (en) 2021-06-23 2022-06-22 A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders

Publications (1)

Publication Number Publication Date
PL4358995T3 true PL4358995T3 (pl) 2026-04-20

Family

ID=82608742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22744054.2T PL4358995T3 (pl) 2021-06-23 2022-06-22 Inhibitor szlaku miostatyny w połączeniu z aktywatorem szlaku glp-1 do stosowania w leczeniu zaburzeń metabolicznych

Country Status (15)

Country Link
US (1) US20240368262A1 (cg-RX-API-DMAC7.html)
EP (2) EP4714494A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024524159A (cg-RX-API-DMAC7.html)
AU (1) AU2022299185A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221555A1 (cg-RX-API-DMAC7.html)
DK (1) DK4358995T3 (cg-RX-API-DMAC7.html)
ES (1) ES3062188T3 (cg-RX-API-DMAC7.html)
FI (1) FI4358995T3 (cg-RX-API-DMAC7.html)
IL (1) IL309078A (cg-RX-API-DMAC7.html)
MX (1) MX2023014840A (cg-RX-API-DMAC7.html)
PL (1) PL4358995T3 (cg-RX-API-DMAC7.html)
PT (1) PT4358995T (cg-RX-API-DMAC7.html)
SI (1) SI4358995T1 (cg-RX-API-DMAC7.html)
TW (1) TW202317175A (cg-RX-API-DMAC7.html)
WO (1) WO2022271867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
JP2025532651A (ja) * 2022-09-21 2025-10-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肥満、糖尿病および肝機能障害を処置する方法
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
IL326224A (en) * 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025219859A1 (en) * 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2025245160A1 (en) 2024-05-21 2025-11-27 Scholar Rock, Inc. Myostatin-selective inhibitors for treating metabolic disorders
WO2026037938A1 (en) * 2024-08-16 2026-02-19 Protuoso Pte. Ltd. Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor
WO2026090182A1 (en) * 2024-10-23 2026-04-30 Emmyon, Inc. Glp-1 receptor agonist and ursolic acid combinations and use thereof for increasing weight loss while improving muscle mass and strength

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US20210087250A1 (en) * 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
SG11202108099WA (en) * 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF

Also Published As

Publication number Publication date
US20240368262A1 (en) 2024-11-07
WO2022271867A1 (en) 2022-12-29
EP4358995A1 (en) 2024-05-01
ES3062188T3 (en) 2026-04-09
FI4358995T3 (fi) 2026-02-04
PT4358995T (pt) 2026-02-17
AU2022299185A1 (en) 2024-01-25
MX2023014840A (es) 2024-02-12
EP4714494A3 (en) 2026-04-22
DK4358995T3 (da) 2026-02-02
TW202317175A (zh) 2023-05-01
JP2024524159A (ja) 2024-07-05
IL309078A (en) 2024-02-01
EP4714494A2 (en) 2026-03-25
SI4358995T1 (sl) 2026-03-31
CA3221555A1 (en) 2022-12-29
EP4358995B1 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
IL309078A (en) A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
ECSP099724A (es) Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer
NZ619520A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PH12015502324A1 (en) Synergistic compositions
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CR11099A (es) Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer
WO2008127975A3 (en) Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
ZA201805403B (en) Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
IL277629A (en) RET inhibitor for use in the treatment of cancer involving a change in RET
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
PT4313058T (pt) Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimune
MX2009013950A (es) Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.
PL4094763T3 (pl) Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem
IL283937A (en) Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment
HK40109739A (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
CL2009002146A1 (es) Compuesto (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y su sal mono-l-malato; su composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por nnr tal como trastornos del snc, inflamacion, trastornos inmunes, entre otros.
EP3813869C0 (en) CCR5 INHIBITOR FOR THE TREATMENT OF A NEUROINFLAMMATORY DISORDER INVOLVING BRAIN INFLAMMATION
IL315471A (en) Use of isatuximab in combination with other agents to treat multiple myeloma
EP4401750C0 (en) COMPOSITION CONTAINS IL-36 AND OPTIONALLY IL-18 FOR USE IN THE TREATMENT OF EYE DISEASES
HK40116642A (en) Cancer treatment using ketotifen in combination with a checkpoint inhibitor
UA39854U (uk) Спосіб лікування головного болю напруги у підлітків з невротичними розладами
GB202209316D0 (en) Novel compositions having a use in therapy
UA40478U (ru) Способ лечения неврастении у подростков